Trial · NCT00890084
Telmisartan Tab Hypertension
NCT00890084, Completed, Boehringer Ingelheim; results first posted 2012-05-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Telmisartan Tab Hypertension. Trials, record NCT00890084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00890084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Telmisartan Tab Hypertension
- NCT number
- NCT00890084
- Status
- Completed
- Enrollment
- 2,913 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Hypertension
- Interventions
- Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
- First posted
- 2009-04-29
- Last updated
- 2014-04-08
- Results first posted
- 2012-05-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Blood Pressure < 140/90 mm Hg | 12 weeks | % of high risk patients with Blood Pressure \< 140/90 mm Hg |
| Secondary | Percentage of Patients With Blood Pressure < 130/80 mm Hg | 12 weeks | |
| Secondary | Absolute Blood Pressure Decrease | baseline and 12 weeks | systolic blood pressure |
| Secondary | BP Response Rate (Drop of Systolic BP of 10mmHg or More) | 12 weeks | BP response rate (drop of systolic BP of ≥ 10mmHg) after approximately 12 weeks of treatment with telmisartan (alone or in fixed combination with HCTZ) |
| Secondary | Treatment Patterns | 12 weeks | Treatment patterns observed at the end of the study as Micardis monotherapy, Micardis Plus 12.5 and Micardis Plus 25 (with or without changes in concomitant antihypertensive medications). |
| Secondary | Change in Concomitant Antihypertensive Drugs Given at Study Entry | baseline and 12 weeks | Percentage of patients who had a change in concomitant antihypertensive drugs prescribed at initiation and after 12 weeks. The antihypertensive drugs were changed (which is stopped, titration of dose and started) or not. |
| Secondary | Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg | 12 weeks | |
| Secondary | Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007 | 12 weeks | Blood pressure should be reduced to at least below 140/90 mm Hg (systolic/diastolic),and to lower values, if tolerated, in all hypertensive patients. Target blood pressure should be lower than 130/80 mmHg in diabetics and in high or very high risk patients |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Blood Pressure < 140/90 mm Hg | 12 weeks | Intention-to-Treat (ITT) | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With Blood Pressure < 130/80 mm Hg | 12 weeks | Intention to Treat (ITT) | Percentage of participants | NUMBER |
| SECONDARY | Absolute Blood Pressure Decrease | baseline and 12 weeks | Intention to treat (ITT) | mm Hg | MEAN |
| SECONDARY | BP Response Rate (Drop of Systolic BP of 10mmHg or More) | 12 weeks | ITT Population | Percentage of patients | NUMBER |
| SECONDARY | Treatment Patterns | 12 weeks | ITT Population | Percentage of patients | NUMBER |
| SECONDARY | Change in Concomitant Antihypertensive Drugs Given at Study Entry | baseline and 12 weeks | Intention to treat (ITT) | percentage of patients | NUMBER |
| SECONDARY | Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg | 12 weeks | Intention to treat (ITT) | percentage of patients | NUMBER |
| SECONDARY | Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007 | 12 weeks | all investigators participating in the trial | percentage of prescribers | NUMBER |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Blood Pressure < 140/90 mm Hg | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 69.6 | 95% Confidence Interval 67.9 to 71.3 | Percentage of participants | |
| Percentage of Patients With Blood Pressure < 130/80 mm Hg | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 13.2 | 95% Confidence Interval 12.0 to 14.5 | Percentage of participants | |
| Absolute Blood Pressure Decrease | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 23.2 | 95% Confidence Interval 22.7 to 23.7 | mm Hg | |
| BP Response Rate (Drop of Systolic BP of 10mmHg or More) | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 91.85 | 95% Confidence Interval 90.8 to 92.6 | Percentage of patients | |
| Treatment Patterns | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | Telmisartan 40mg | 4.7 | Percentage of patients | |
| Treatment Patterns | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | Telmisartan 80mg | 49.4 | Percentage of patients | |
| Treatment Patterns | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | Telmisartan 40/12,5mg | 3.3 | Percentage of patients | |
| Treatment Patterns | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | Telmisartan 80/12,5mg | 29.7 | Percentage of patients | |
| Treatment Patterns | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | Telmisartan 80/25mg | 12.6 | Percentage of patients | |
| Change in Concomitant Antihypertensive Drugs Given at Study Entry | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 13.6 | 95% Confidence Interval 12.3 to 14.9 | percentage of patients |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 2,913 | |
| Overall Study | COMPLETED | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 2,771 | |
| Overall Study | NOT COMPLETED | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 142 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Umbilical hernia | Gastrointestinal disorders | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 1 | 2,771 | |
| serious | Alcohol detoxification | Surgical and medical procedures | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 1 | 2,771 | |
| serious | cerebral hemorrhage, fatal | Vascular disorders | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 1 | 2,771 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | ||
| Total, other adverse events | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 0 | 2,771 |
| Total, serious adverse events | Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) | 3 | 2,771 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00890084
GET https://conductscience.org/api/trials/v1/NCT00890084/registered